12 Month Price Forecast For BIO
Distance to BIO Price Forecasts
BIO Price Momentum
๐ค Considering Bio-Rad (BIO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 8:59 PM UTC
BIO Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, BIO has a consensus that is bullish. The median price target is $410.00, with forecasts ranging from $315.00 to $477.00. Currently, there are 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With BIO currently trading at $346.03, the median price forecast suggests a 18.5% upside. The most optimistic forecast comes from at , projecting a 37.8% upside, while at Jefferies provides the most conservative target, suggesting a -9.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIO Analyst Consensus
BIO Price Target Range
Latest BIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIO.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 14, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $481.00 |
Dec 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $481.00 |
Oct 31, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $450.00 |
Oct 31, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $469.00 |
Oct 1, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $400.00 |
Aug 27, 2024 | Wells Fargo | Brandon Couillard | Equal-Weight | Initiates | $340.00 |
Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $401.00 |
Aug 2, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $401.00 |
Aug 2, 2024 | Citigroup | Patrick Donnelly | Neutral | Maintains | $350.00 |
Jun 3, 2024 | Jefferies | Hold | Assumes | $315.00 | |
May 8, 2024 | UBS | Dan Leonard | Buy | Maintains | $385.00 |
Apr 3, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $365.00 |
Feb 16, 2024 | UBS | Dan Leonard | Buy | Maintains | $420.00 |
Feb 16, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $480.00 |
Dec 7, 2023 | UBS | Dan Leonard | Buy | Initiates | $395.00 |
Aug 7, 2023 | Wells Fargo | Dan Leonard | Overweight | Maintains | $525.00 |
Aug 4, 2023 | RBC Capital | Conor McNamara | Outperform | Maintains | $524.00 |
Aug 4, 2023 | Credit Suisse | Dan Leonard | Outperform | Maintains | $550.00 |
Jun 16, 2023 | Wells Fargo | Dan Leonard | Overweight | Initiates | $550.00 |
May 8, 2023 | RBC Capital | Conor McNamara | Outperform | Maintains | $531.00 |
Stocks Similar to Bio-Rad Laboratories Inc
The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Rad Laboratories Inc (BIO) Financial Data
Bio-Rad Laboratories Inc has a market capitalization of $9.71B with a P/E ratio of -16.0x. The company generates $2.58B in trailing twelve-month revenue with a -30.2% profit margin.
Revenue growth is +2.8% quarter-over-quarter, while maintaining an operating margin of +9.9% and return on equity of -9.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Bio-Rad Laboratories Inc (BIO) Company Overview
About Bio-Rad Laboratories Inc
Manufactures life science and diagnostic products.
The company operates through two segments: Life Science and Clinical Diagnostics. It generates revenue by developing, manufacturing, and marketing a wide range of instruments, systems, reagents, and consumables used in the separation and analysis of biological materials, as well as test systems and quality controls for medical laboratories.
Founded in 1952 and headquartered in Hercules, California, the company serves various markets including proteomics, genomics, and food safety, distributing products through a direct sales force and various intermediaries across multiple regions globally.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,700
CEO
Mr. Norman D. Schwartz
Country
United States
IPO Year
1980
Website
www.bio-rad.comBio-Rad Laboratories Inc (BIO) Latest News & Analysis
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
9 days agoBio-Rad Laboratories, Inc. will report Q4 and full-year 2024 financial results on February 13, 2025, after market close, with a conference call at 2 PM PT.
Bio-Rad's upcoming financial results announcement may impact stock prices and investor sentiment, revealing performance trends and future guidance critical for decision-making.
BIO's strong performance in ddPCR technology and growth in clinical diagnostics suggests positive prospects for investors.
BIO's strong ddPCR platform performance and clinical diagnostics growth signal potential revenue increases, enhancing investor confidence and possibly driving stock value.
Geneoscopy has secured $105 million in a Series C funding round, with Bio-Rad Laboratories as the lead investor.
Geneoscopy's $105 million funding boosts its financial strength, signaling potential growth and innovation, which could positively impact stock performance and market confidence in biotech investments.
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference
1 month agoBio-Rad Laboratories' executives will meet with analysts and investors at J.P. Morgan's 43rd Annual Healthcare Conference in San Francisco from January 13-16, 2025.
Bio-Rad's leadership meetings at a major healthcare conference signal potential strategic updates and insights, influencing investor sentiment and stock performance.
Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference
2 months agoBio-Rad Laboratories (NYSE: BIO, BIO.B) will hold one-on-one meetings with analysts and investors at Citi's 2024 Global Healthcare Conference on December 3-5, 2024.
Bio-Rad's leadership engaging with analysts at a major healthcare conference signals potential insights into company performance and strategy, which can influence stock valuations and investor sentiment.
Bio-Rad's overseas revenue trends are influencing Wall Street forecasts and the company's stock outlook, impacting investor sentiment and potential growth.
Bio-Rad's overseas revenue trends can influence earnings forecasts, impacting stock performance and investor sentiment regarding future growth potential.
Frequently Asked Questions About BIO Stock
What is Bio-Rad Laboratories Inc's (BIO) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Bio-Rad Laboratories Inc (BIO) has a median price target of $410.00. The highest price target is $477.00 and the lowest is $315.00.
Is BIO stock a good investment in 2025?
According to current analyst ratings, BIO has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $346.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BIO stock?
Wall Street analysts predict BIO stock could reach $410.00 in the next 12 months. This represents a 18.5% increase from the current price of $346.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bio-Rad Laboratories Inc's business model?
The company operates through two segments: Life Science and Clinical Diagnostics. It generates revenue by developing, manufacturing, and marketing a wide range of instruments, systems, reagents, and consumables used in the separation and analysis of biological materials, as well as test systems and quality controls for medical laboratories.
What is the highest forecasted price for BIO Bio-Rad Laboratories Inc?
The highest price target for BIO is $477.00 from at , which represents a 37.8% increase from the current price of $346.03.
What is the lowest forecasted price for BIO Bio-Rad Laboratories Inc?
Price targets from Wall Street analysts for BIO are not currently available. The stock is trading at $346.03.
What is the overall BIO consensus from analysts for Bio-Rad Laboratories Inc?
The overall analyst consensus for BIO is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $410.00.
How accurate are BIO stock price projections?
Stock price projections, including those for Bio-Rad Laboratories Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.